DIN 02479656 — HEMLIBRA 105 MG
HEMLIBRA is a solution of Emicizumab marketed by HOFFMANN-LA ROCHE LIMITED. The full Emicizumab monograph covers indications, dosing, interactions and counselling for every strength and manufacturer.
- DIN
- 02479656
- Brand name
- HEMLIBRA
- Active ingredient
- Emicizumab
- Strength
- 105 MG
- Dosage form
- SOLUTION
- Route
- SUBCUTANEOUS
- Manufacturer
- HOFFMANN-LA ROCHE LIMITED
- Health Canada status
- MARKETED
- Drug class
- Bispecific monoclonal antibody (Factor VIIIa mimetic)
Product data from the Health Canada Drug Product Database, synced . Verify the live status at Health Canada.
Other Emicizumab products
| DIN | Brand | Strength | Form | Manufacturer | Status |
|---|---|---|---|---|---|
| 02556049 | HEMLIBRA | 12 MG | SOLUTION | HOFFMANN-LA ROCHE LIMITED | MARKETED |
| 02479664 | HEMLIBRA | 150 MG | SOLUTION | HOFFMANN-LA ROCHE LIMITED | MARKETED |
| 02479621 | HEMLIBRA | 30 MG | SOLUTION | HOFFMANN-LA ROCHE LIMITED | MARKETED |
| 02556057 | HEMLIBRA | 300 MG | SOLUTION | HOFFMANN-LA ROCHE LIMITED | MARKETED |
| 02479648 | HEMLIBRA | 60 MG | SOLUTION | HOFFMANN-LA ROCHE LIMITED | MARKETED |